康灃生物科技（上海）股份有限公司（以下简称“康灃生物”，股票代码：06922）于2026年2月5日发布2026年1月股份变动月报。报告期截至2026年1月31日，公司注册股本由上月底的239,110,000股增至244,705,000股。
报告显示，H股股份从上月底的143,438,579股增至149,033,579股，增发数量为5,595,000股，发行价格为每股5.36港元。非上市股份保持在95,671,421股不变。本月无股份购回、注销或库藏股变动，也无股份期权及其他股权激励计划的调整。
截至本月末，公司已发行股份总数达到244,705,000股，较上月底有所增加。公告称，公司确认已遵守香港联交所《上市规则》及其他相关法律法规。
本次月报由公司董事朱军签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.